RXi Pharmaceuticals Reports Third Quarter EPS of $(0.23)

RXi Pharmaceuticals Corporation RXII today reported its financial results for the third quarter ended September 30, 2010. As of September 30, 2010, cash, cash equivalents and short-term investments totaled $8.8 million, compared with cash and cash equivalents of $5.7 million at December 31, 2009. For the third quarter of 2010, the Company reported a net loss of approximately $4.1 million compared with a net loss of $3.0 million for the same period in 2009. The result is a net loss of $0.23 per share for the third quarter of 2010 on both a basic and diluted basis, based on 18.4 million weighted average shares outstanding, compared with a net loss of $0.19 per share on both a basic and diluted basis, based on 15.3 million weighted average shares outstanding, for the third quarter of 2009.